Member Info for draft

They need to rns that production has started IF it has and that the repairs are complete

given theres been no rns, strongly suggests its all turned off right now

turn the wells back on

total idiots running this into the ground

AL
@OilinvestorAl
·
8m
#BRENT has just hit $46.5/ bbl. That’s the highest #oil price since March. #Oott

About to pay the ceo of works 15mill refund

Tr1 holder goes near to 10%!

Im holding all the way up.

just realised the blacked out seats when booking online are blocked out to keep distancing

Fully sold out for tomorrow at my local Odeon, booooom!

High rate manufacture of printed NFC microcontroller circuits to transfer COVID-19 point of need antibody diagnostic test results to the Cloud

Covid 19 grant won
NFC-4-COVID-19 aims to increase the manufacturing rate of NFC flexible circuit boards from 10,000/hour to over 400,000/hr using advanced manufacturing processes which are typically used in the food packaging and printed label industry. The step change in manufacturing rate of NFC circuits and their inclusion in each COVID-19 antibody diagnostic device for home testing allows critically important pandemic mapping data to be available in the cloud for analysis within seconds. This is essential to establish a significant sample size for robust statistical analysis to allow governments to take the correct action quicker to control the spread of the disease throughout the population and to allow informed decision to be made on when lock-downs should be enforced or removed. NFC-4-COVID-19 provides one part of the solution to pandemic management, where antibody tests are distributed through postal services to every citizen and following simple instructions allows a test to run and the test data immediately sent to a secure cloud based data management and dash board system. Without NFC connectivity other forms of data transfer are needed to transfer data from the diagnostic to a SMART phone and then to the Cloud. Optical techniques suffer from poor signal to noise, whilst dierect electrical sensing is more robust. The later is the preferred approach for COVID-19 antibody tests.

The project builds on proprietary materials and manufacturing methods developed for long range RFID tags and labels and applies these to make smart phone readable labels and devices. The extreme production rate will enable point of need diagnostics to be developed which immediately transfers sensor data, geo-location and user information to the Cloud for analysis and display by artificial intelligence algorithms, distributed ledger, blockchain and other Cloud Computing platforms, such as Microsoft Azure.

In addition, the unique multi-layer process will be more sustainable allowing more complex circuitry to be produced on smaller circuit boards which use less material. Such advances will allow very compact distribution track and trace labels to be produced which may log the environmental temperatures and humidity seen by sensitive goods during storage and distribution.

https://www.londonstockexchange.com/news-article/AZN/ph-i-trial-begins-for-covid-19-monoclonal-antibody/14664066

be interesting if they can knock out a diabetes specific covid 19 test with Flexotronix

Professor Stevens is currently working on:

Connected digital manufacture of Medical Devices
Flexible light emitting optoelectronic devices
Point-of-Care disposable diagnostic device for the early detection of the onset of Type II diabetes. In collaboration with The University of Cardiff and the Science and Technology Facilities Council
Scale up of high speed printing technology for flexible electrodes and circuits on thin plastic film.
Developing collaborative projects which integrate, electrospinning, nano-electrospray, laser ablation and annealing.

Flexotronix

Pharm2Farm (Lead) and Flexotronix (subcontractor) aim to combine their leading nanotechnology capabilities to produce a highly enhanced anti-viral face mask to meet N95/FFP2 and FFP3 specifications.

Bob Stevens
Professor in Smart Materials and Devices
School of Science & Technology
Role
Professor of SMART Materials and Devices (Part time)

Research Areas

Electrospinning of natural and synthetic polymers to produce microstructured functional nanofibrous membranes for applications in Life Science, Healthcare, Energy and Environment
Point of Care and Self Diagnostic devices for early detection of disease (Type II Diabetes, Cadiovascular)

People with type 2 diabetes are twice as likely to die from coronavirus as those without it, according to new research from NHS England.

The study, conducted with Imperial College London, also found that those with type 1 diabetes were three and a half times more likely to die.

Overall, 7,466 virus patients who have died in hospitals in England had type 2 diabetes and 365 had type 1, accounting between them for 32 per cent of deaths up to May 17.

Diabetics face a significantly higher risk of dying from Covid-19, with one in three of all coronavirus hospital deaths in England being associated with the illness.

interesting the RMS partner makes a diabetes testing kit

Point of Care and Self Diagnostic devices for early detection of disease (Type II Diabetes, Cadiovascular)

https://www.thetimes.co.uk/article/investors-back-potential-drug-for-diabetic-covid-19-patients-06dm759n8

A project to develop a potential coronavirus treatment for diabetics, headed by Sir Christopher Evans, one of Britain’s leading biotechnology entrepreneurs, has raised £10 million from investors and has begun an advanced clinical trial.

The phase two trial, called Arcadia, involving 150 patients in 30 hospitals in Britain, began at the weekend after approval was granted by the Medicines and Healthcare product Regulatory Agency. Pre-clinical research has suggested that the glucose kinase activator could aid diabetes sufferers who contract Covid-19.

The trial is expected to last a minimum of three to four months and a further later-stage trial may follow. It involves a compound developed by Astrazeneca, one of Britain’s two leading pharmaceuticals companies, which was licensed to St George Street, a medical charity led by academics and former drugs industry executives.

St George Street approached Sir Christopher, 62, to help to raise funds for the project via his Excalibur Medicines vehicle, which has taken responsibility for running the programme.

The British government, Mubadala, the United Arab Emirates’ sovereign wealth fund, and Sir Christopher have put in roughly equal funds and the venture also is being supported by high-net-worth individuals.
Diabetics face a significantly higher risk of dying from Covid-19, with one in three of all coronavirus hospital deaths in England being associated with the illness, Sir Christopher said. If the trials proved successful, Sir Christopher said that he would pursue commercialising the drug, potentially through a sale to a big pharmceuticals company, with the London-listed Astrazeneca the “first port of call”.

do one.,

havent sold even 1 share. they get this proved up this is going gangbusters

Forest Road’s new brewery will open in South Bermondsey, on top the spot that used to host historical tea company, The Mazawattee

Ground works for the site began in June 2020. It will be capable of producing 30,000/hl a year, although the brand expects to brew only 11,000hl in the first 12 months of activity.

The brewery will feature a semi-automatic, 50-barrel, four-vessel brewhouse, partially designed by brewer Vinnie Cilurzo of Russian River.

‘The brewhouse will change Forest Road, because I'll finally be able to brew my own ****ing beer again,’ said Brown, who has been making his beer under contract since Forest Road’s foundation in 2015. ‘Customers can expect what they get now, but a 20% increase in quality.’

The brewery is expected to become operational by early 2021.

Brown and head brewer James Garstang will be producing Posh lager and Work IPA, which are currently being brewed under contract, as well as other ‘nuanced, subtly complex, drinkable beers’.

Brown announced that he’s going to ‘christen’ the kit with a barley wine, ‘with as much grist as I can possibly put in it and then rack that into barrels to forget about…

‘We are undoubtedly going to belt out a rude-boy IPA...’ he continued, ‘and we really want to start exploring dark and amber lagers and porters… One thing is for sure. Forest Road won’t be doing things because they’re fashionable or easy… James and I both appreciate the cradle of tight, subtle yet confident flavor-profiles in beers made for drinking.

https://www.forestroad.co.uk/

new client!